Delivering through innovating cancer therapeutics
Defeating Cancer
Our Story
OurStory
Speratum Biopharma was founded to transform groundbreaking research into effective cancer treatments. Led by Dr. Christian Marín Müller, a pioneer in oncological biotechnology, our team combines expertise in molecular biology, nanotechnology, and precision medicine to address the urgent need for better patient outcomes. Despite advances in cancer research, many therapies still rely on broad-spectrum approaches with inconsistent results, leading to prolonged treatments.
At Speratum, we are changing this by developing miRNA-based therapies that target cancer at its core, offering more precise and effective solutions. Guided by scientific innovation and a commitment to saving lives, we are shaping a new era in cancer care—one where innovation drives real patient impact.
Precision Oncology: Turning Hope into Life-Changing Reality.
Precision Oncology: Turning Hope into Life-Changing Reality.
Our Mission
We are committed to delivering cutting-edge, targeted cancer therapies—swiftly, effectively, and with life-changing outcomes.
Our Vision
We envision a cancer-free world, where breakthrough therapies offer real hope and transformative change for every patient in need.
A future without cancer
A future without cancer
Speratum Biopharma is committed to pioneering breakthrough therapies that harness the power of microRNA-based technologies to target and inhibit dysregulated pathways associated with cancer and other challenging diseases. Our primary focus is on precision oncology, where microRNA drivers are critical in tumor progression, and there is a significant unmet need for effective treatments. Leveraging our proprietary platforms, Nano-In™ and NoPass™, we aim to deliver targeted therapies that offer new hope for patients battling solid tumors and other high-burden cancers.
Beyond oncology, we are exploring the broader potential of microRNA modulators to address other complex, genetically defined conditions where traditional therapies have fallen short.
Our technology foundation is built upon years of cutting-edge research and innovation, driven by our leadership in nucleic acid therapeutics. At Speratum, we continuously push the boundaries of science to transform patient outcomes and redefine the possibilities in precision medicine
Our Technology
Our Technology
miR-198
Speratum Biopharma’s miR-198 represents a groundbreaking therapeutic scaffold, targeting pleiotropic mechanisms central to cancer progression. As a key tumor suppressor microRNA, miR-198 is notably downregulated in various cancers, offering a powerful therapeutic hypothesis for combating malignancies. By leveraging Speratum’s innovative platform technologies, the therapeutic potential of miR-198 is unlocked, enabling it to address a wide range of cancer types. miR-198 acts as a central control point, regulating critical processes that suppress tumor growth, inhibit cancer cell migration, and overcome drug resistance. This multifaceted approach positions miR-198 as a transformative tool in the fight against cancer, advancing precision oncology to new heights.
NoPass Design
The NoPass™ Platform represents a breakthrough in RNA interference (RNAi) therapy design, enabling the creation of potent RNA molecules with higher specificity and fewer side effects. This innovative system uses proprietary algorithms to engineer optimized RNA sequences that increase targeting accuracy while limiting off-target effects.
Nano-In
The Nano-In™ Platform is a revolutionary drug delivery system. Utilizing a proprietary biocompatible polymer, Nano-In™ forms nanoparticles that precisely target cancer cells. This platform optimizes the delivery of nucleic acids directly to tumor sites, ensuring protection from degradation, maximizing potency, and minimizing off-target effects. The result is a delivery system that reduces toxicity while enhancing therapeutic impact, leading to safer and more effective treatments.
NM-198 Fully loaded
NM-198™ is Speratum’s flagship therapeutic candidate, designed to harness the tumor-suppressing power of miR-198. By combining the Nano-In™ and NoPass™ platforms, NM-198™ disrupts key cancer pathways, targeting multiple oncogenic factors involved in tumor growth, migration, and drug resistance, while ensuring superior delivery, enhanced efficacy, and reduced side effects.
Our Approach
Our Approach
Harnessing Innovation to Redefine Cancer Treatment
Revolutionizing Cancer Treatment with Precision RNA Innovation
At Speratum Biopharma, we combine advance molecular science with cutting edge delivery technologies. By leveraging miR-198 and our proprietary NoPass and Nano-in platforms, we have engineered NM-198, a ground breaking therapeutic designed to target challenging cancers with precision. Our approach integrates innovative RNA based solutions and optimized delivery mechanisms to ensure the safety and efficiency of cancer treatment. Join us in our mission to transform oncology through precision medication and pioneering technology.
Revolutionizing Cancer Treatment with Precision RNA Innovation |
Choose your pathway
Our Publications
Our Publications
Meet the Executive Team
At Speratum Biopharma, we bring together a team of leading experts in mRNA therapeutics, precision oncology, and biopharmaceutical innovation. Our multidisciplinary team includes pioneers in RNA-based medicine, molecular biology, cancer therapeutics, and translational research, with decades of collective experience and a track record of impactful publications and patents. Together, we are committed to advancing cutting-edge solutions to address the most challenging cancers.
